Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company

Refine Search
Big Pharma
Pharmaceutical companies will suffer an estimated $65 billion drop in sales over the next five years due to the expiry of patents protecting several leading drugs, according to a UK research and consulting firm.   12 December 2014
Americas
Pharmaceutical company Supernus and its subsidiary Galderma have had their Oracea (doxycycline) acne treatment drug protected from a generic challenge, in a decision dubbed the “first of its kind”.   11 December 2014
Europe
Law firm King & Spalding has appointed a partner to its office in Washington, DC.   10 December 2014
Americas
Pharmaceutical company Merck has said it will press on with an $8.4 billion buyout of Cubist Pharmaceuticals despite a court ruling that could pave the way for a generic version of a lucrative Cubist drug.   10 December 2014
Americas
Novartis’s generic arm Sandoz has failed to win a patent case regarding its biosimilar version of Amgen’s psoriasis and arthritis drug Enbrel (etanercept).   9 December 2014
Americas
A US court has spared drug companies AstraZeneca and Ranbaxy Laboratories a potentially hefty fine after ruling that a ‘pay-for-delay’ deal between them did not violate antitrust grounds.   8 December 2014
Americas
US research centre the Broad Institute of Massachusetts Institute of Technology and Harvard has entered into a worldwide licensing deal with Editas Medicines, granting it access to IP covering genome technology and human therapeutic applications.   5 December 2014
Americas
The US Court of Appeals for the Federal Circuit has overturned a decision on patent claims for a drug used to treat anorexia and cachexia in AIDS patients.   4 December 2014
Americas
Drugs companies Cipla and Meda Pharmaceuticals have sued Canada-based Apotex as they seek to protect the nasal spray Dymista (Azelastine hydrochloride, fluticasone propionate).   3 December 2014
Asia-Pacific
Japanese drug maker Otsuka Holdings has agreed to buy Avanir Pharmaceuticals as part of a multi-billion dollar deal that could ease its potential patent woes.   2 December 2014